EUVIMEDSkopri EUVIMED
Crossref

The eukaryotic elongation factor 2 kinase inhibitor, A484954, induces hypoglycaemic and hypotensive effects

Tomoko Kodama, Satoshi Kameshima, Kosuke Otani, Muneyoshi Okada, Hideyuki Yamawaki

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17443 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Tomoko Kodama and 4 co-authors. Institution: Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Towada, Japan. Major MEDLINE topics: Elongation Factor 2 Kinase, Hypoglycemic Agents, Antihypertensive Agents, Protein Kinase Inhibitors. Cited 1 times so far (Crossref); 55 references. Funded by: Japan Society for the Promotion of Science (JSPS) KAKENHI, Kitasato University Research Grant for Young Researchers, Kitasato University Research Grant.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose Eukaryotic elongation factor 2 kinase (eEF2K) belongs to the Ca 2+ /calmodulin‐dependent protein kinase family. We previously revealed that A484954, a selective eEF2K inhibitor, caused hypotensive and diuretic effects via the production of nitric oxide (NO) in spontaneously hypertensive rats. Otsuka Long–Evans Tokushima Fatty (OLETF) rats are hypertensive because of obesity and type 2 diabetes. Because an NO synthase inhibitor was reported to increase the expression of sodium glucose co‐transporter 2 (SGLT2), we hypothesised that A484954 causes not only hypotensive but also hypoglycaemic effects via NO production in OLETF rats. Experimental Approach To test the hypothesis, we examined the effects of A484954 administration on hyperglycaemia and hypertension in OLETF rats. OLETF rats were given an intraperitoneal injection of A484954 (2.5 mg kg −1 day −1 ) for 7 days. Then, we measured blood and urinary glucose level, urine output, systolic blood pressure and ventricular contractility. We also conducted Western blotting and isometric tension measurements. Key Results A484954 induced a decrease in blood glucose, an increase in urinary glucose excretion, and a decrease in protein expression of kidney SGLT2. In addition, A484954 induced a decrease in systolic blood pressure, an NO‐dependent vasorelaxation, and a diuretic effect. Further, A484954 enhanced left ventricular contractility. Conclusion and Implications We, for the first time, revealed that (1) A484954 caused hypoglycaemic effects through increasing urinary glucose excretion via decreasing SGLT2, (2) A484954 improved diabetic complication, including hypertension, through vasorelaxation and diuresis via NO production, and (3) A484954 had a positive inotropic effect.

Subjects

MeSH terms (MEDLINE)

Elongation Factor 2 KinaseHypoglycemic AgentsAntihypertensive AgentsProtein Kinase InhibitorsAnimalsMaleRatsBlood GlucoseRats, Inbred OLETFHypertensionBlood PressureNitric OxideSodium-Glucose Transporter 2

Author keywords

cardiotonic effectsdiuresiseukaryotic elongation factor 2 kinase inhibitorhypoglycaemic effectshypotensive effectsnitric oxidesodium glucose co‐transporter 2

Substances

Elongation Factor 2 KinaseBlood GlucoseNitric OxideHypoglycemic AgentsAntihypertensive AgentsProtein Kinase InhibitorsSodium-Glucose Transporter 2

Authors and institutions

  • Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Towada, Japan.
  • Laboratory of Small Animal Internal Medicine, School of Veterinary Medicine, Kitasato University, Towada, Japan.

Funding

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Kitasato University Research Grant for Young Researchers
  • Kitasato University Research Grant
  • Japan Society for the Promotion of Science

Cite

APA

Kodama, T., Kameshima, S., Otani, K., Okada, M., & Yamawaki, H. (2025). The eukaryotic elongation factor 2 kinase inhibitor, A484954, induces hypoglycaemic and hypotensive effects. British Journal of Pharmacology. https://doi.org/10.1111/bph.17443

Vancouver

Kodama T, Kameshima S, Otani K, Okada M, Yamawaki H. The eukaryotic elongation factor 2 kinase inhibitor, A484954, induces hypoglycaemic and hypotensive effects. British Journal of Pharmacology. 2025. doi:10.1111/bph.17443

BibTeX
@article{Kodama2025,
  author = {Kodama, Tomoko and Kameshima, Satoshi and Otani, Kosuke and Okada, Muneyoshi and Yamawaki, Hideyuki},
  title = {The eukaryotic elongation factor 2 kinase inhibitor, A484954, induces hypoglycaemic and hypotensive effects},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17443}
}
Start for free →